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Background: Juvenile-onset Systemic Lupus Erythematosus (JSLE) patients may develop lupus nephritis (LN) during their initial presentation, or later in their disease. The study aimed to assess if clinical/demographic factors characterise patients with LN within the UK JSLE Cohort Study, and whether such factors predict subsequent LN development. Methods: Univariate logistic regression modelling compared clinical/demographic factors in patients with/without LN at baseline. For those who subsequently developed LN, Cox Proportional-hazard modelling was used to test the association between such factors and time to LN development. Covariates with p<0.2 univariately were included within a multiple-regression model. Results: 121/331 (37%) of patients presented with active LN at baseline, with first ACR score (p<2.0x10-16), severe hypertension (p=0.0006), proteinuria (p<2.0x10-16), creatinine (p=1.0x10-16), ESR (p=1.0x10-16), neutrophils (p<2.0x10-16), C3 (p=4.0x10-16) and ethnicity (p=3.0x10-13) differing between those with/without LN. Of the 210 without active LN at baseline, 13 patients had a single visit and were excluded from further analysis. 34/197 (17%) developed LN after a median of 2.04 years [inter-quartile range, IQR 0.8-3.7], with higher ACR scores (p=0.014, hazard ratio (HR) =1.45, 95% confidence interval (CI)=1.08-1.95) and lower C3 levels (p=0.0082, HR=0.27, 95% CI=0.10-0.68) demonstrated as predictors of subsequent LN. Conclusions: Clinical/demographic factors can help to characterise patients at increased risk of LN. 
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Introduction

Juvenile-onset systemic lupus erythematosus (JSLE) is a life-threatening multi-system autoimmune disease, which demonstrates a more aggressive course when the onset is within childhood []. Renal manifestations occur more frequently in JSLE than adult-onset systemic lupus erythematosus (SLE), with up to 80% of JSLE patients developing lupus nephritis (LN) within the first 5 years from diagnosis  ADDIN EN.CITE []. Many patients will have LN as part of their initial presentation, but a proportion will go on to develop this manifestation at a later stage  ADDIN EN.CITE [, ]. Early recognition and appropriate management of LN is important as early response to treatment is known to be associated with better renal outcomes  ADDIN EN.CITE []. Long term survival of JSLE  ADDIN EN.CITE [] and adult-onset SLE patients [] with LN is reduced as compared to those without LN. Identifying those with or at risk of developing LN is important, so that clinicians can be particularly vigilant in monitoring for LN. 

To date, investigation of clinical and demographic factors predicting future LN development in children has been limited to a single small North American study including 47 patients  ADDIN EN.CITE []. This study identified low serum albumin (odds ratio (OR) 4.8, 95% CI: 1.9–12.5) and positive dsDNA antibodies (OR 3.2, 95% CI: 1.7–5.9) to be associated with development of LN within a median of 3.32 years from the initial JSLE diagnosis. In longitudinal analyses, the same study identified isolated sterile pyuria [hazard ratio (HR) 3, 95% confidence interval (CI): 1.1–6.4] and low serum albumin (HR 3.4, 95% CI: 1.7–6.9) to be predictors of future LN  ADDIN EN.CITE []. This study included predominantly African American patients. 

Further exploration of such potential predictive factors is required in other ethnically distinct populations, to help clinicians when monitoring patients and making treatment decisions. This study therefore aimed to characterise patients with LN at baseline, and how they differ from patients without LN in terms of clinical and demographic factors. For those without LN at baseline, who develop it at a later stage, the study also sought to determine when they develop LN and whether there are clinical and demographic factors at baseline which can predict subsequent development of LN.

Methods
Patients
Participants of the UK JSLE Cohort Study  ADDIN EN.CITE [] between 2006-16 were included in the current study if they were aged < 16 years at the time of diagnosis, met ≥4 of the American College of Rheumatology (ACR) SLE classification criteria, and their initial paediatric rheumatology visit was within 1 year of receiving their JSLE diagnosis. Patients were excluded if they only had a single study follow-up visit. JSLE clinical disease activity data and laboratory results were collected using the British Isles Lupus Assessment Grade (BILAG) disease activity score  ADDIN EN.CITE []. Demographic details were collected using a standardized UK JSLE Cohort study case report form  ADDIN EN.CITE []. Written patient assent / consent and parental consent was obtained for inclusion of the patients within the UK JSLE Cohort Study, and the cohort study had full ethical approvals in place from the National Research Ethics Service North West, Liverpool East (REC reference 06/Q1502/77). The research was carried out in accordance with the declaration of Helsinki.

Renal disease activity classification
Patients were categorized as having active LN if they had biopsy defined LN (International Society of Nephrology / Renal Pathology Society 2003 score)  ADDIN EN.CITE [] or renal BILAG defined active LN  ADDIN EN.CITE []. The renal domain of the BILAG score is defined as follows; BILAG grade A/B: severe, moderate renal disease respectively, grade C: mild renal disease, grade D: inactive disease but previous renal system involvement, grade E: renal system has never been involved. Six clinical features are considered within the composite renal BILAG score including renal function (deterioration based on serum creatinine and GFR), proteinuria (defined by urine dipstick or urine protein or albumin creatinine ratio or 24 hour protein levels), nephrotic syndrome, active urinary sediment, hypertension, and histological evidence of active nephritis in the previous three months  ADDIN EN.CITE []. Therefore, using the renal BILAG score patients with a score of A or B were defined as having active LN, and those with a D or E were classed as having no LN. Patients with renal BILAG C episodes were excluded from these analyses as such a score can be achieved with relatively minor clinical abnormalities (e.g. 1+ proteinuria on urine dipstick) which may not be reliably attributed to definite active LN. 

Clinical and demographic factors 
Data on clinical and demographic factors were collected at baseline (defined as the initial paediatric rheumatology visit within the first year of JSLE diagnosis) and included within the analyses. The demographic factors included in the analysis were gender, age at JSLE diagnosis, ethnicity (caucasian/non-caucasian) and any family history (FH) of autoimmunity (including SLE, thyroid disease, rheumatoid arthritis, connective tissue disease, type-1 diabetes, ‘other family history’ documented). 

Clinical factors collected (as part of routine clinical care) included:
	Renal features – proteinuria (spot protein/creatinine or albumin/creatinine ratio, normal range <20 mg/mmCr), severe hypertension [blood pressure rising to > 170/110 mm Hg within 1 month with grade 3 or 4 Keith-Wagener-Barker retinal changes (flame-shaped haemorrhages or cotton-wool spots or papilloedema)], serum creatinine (normal range 49-81 mols/l) and estimated glomerular filtration rate (eGFR).
	Haematological features – haemoglobin (normal range 11.8-16 g/dl), white cell count (normal range 3.9-9.9 x109/L), neutrophils (normal range 1.4-7.5 x109/L), lymphocytes (normal range 1.5-7.6 x109/L) and platelets (normal range 150-400 x109/L).
	Immunological features - complement factors 3 and 4 (C3 normal range 0.90-1.88 g/l, C4 normal range 0.18-0.42 g/l), anti-double-stranded DNA antibody titres (anti-dsDNA), immunoglobulins (IgG normal range 6.13-15.5 g/l, IgA normal range 0.44-2.63 g/l, IgM normal range 0.47-2.57 g/l), antinuclear antibody titre (ANA), anti-smooth muscle antibody (anti-Sm), anti ribonucler protein antibody (anti-RNP), anti-Ro, anti-La, erythrocyte sedimentation rate (ESR normal range 2-8 mm in 1 hour) and c-reactive protein (CRP normal range <4.0 mg/l).
	Concomitant BILAG domain involvement (score of A or B for a given organ domain) - constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, opthalmological and haematological.
	First ACR score []. 

Statistical analysis
To characterise patients with LN at baseline, patients with and without active LN were compared in terms of the clinical and demographic factors detailed above using univariate logistic regression (for continuous or binary distributed data) or a chi-square test (if variables are discrete with more than 2 categories). A Bonferroni correction was applied for multiple testing (35 tests) and the significance level adjusted to 0.00142. For variables with missing values, a complete case analysis was undertaken. 

We next performed multiple regression analysis for the variables with strong association (adjusted p-value<0.2) with LN. Variables with missing data were imputed, and ‘MICE’ package in R version 3.2.0 was used to undertake multiple imputation []. Covariates to be included in the final model were chosen using a backward stepwise model selection procedure (threshold p<0.05). Odds ratio (95% Confidence interval) and p-values were summarised. 

Those without LN at baseline with >1 study visit were followed for subsequent LN development. The association between time to the development of LN and each clinical and demographic variable at baseline was tested univariately using Cox Proportional hazard regression modelling. Patients who did not develop LN during follow-up were censored at the date of the last visit.  In the Cox regression analyses variables with missing data were again tested with complete cases only. Covariates with a p<0.2 on univariate analysis were included in a multiple Cox regression model. Covariates to be included in the final model were chosen using a backward stepwise model selection procedure (threshold p<0.05). HRs, 95% CIs and p-values were summarised for covariates present in the final model, and the results were displayed graphically with Kaplan-Meier curves and risk tables. All analysis and preparation of figures was undertaken with R version 3.2.0 [].

Results
Clinical features of patients with active LN at baseline 
The study cohort consisted of 331 patients, of which 121/331 (37%) presented with active LN at baseline. Testing the association between clinical and demographic factors at baseline and outcome univariately, six factors differed significantly (p<0.00142) between active LN and non-LN patients after correction for multiple testing, including first ACR score (p=3.6x10-6), severe hypertension (p=0.0006), proteinuria (p=5.7x10-12), serum creatinine (p=0.00024), ESR (p=0.00075) and C3 (p=1.3x10-7) (see Table 1). 

After applying variable selection within a multiple regression model, we identified several risk factors for LN development at the initial presentation of JSLE, including having a high first ACR score (p<2.0 x10-16), presence of proteinuria (p<2.0 x10-16), higher serum creatinine values (p=1.0 x10-16), elevated neutrophils (p<2.0 x10-16), increased ESR (p=1.0 x10-16), low C3 values (p=4.0 x10-16), and presence of severe hypertension (p=6.0 x10-9). The risk of LN development was lower for those of Caucasian ethnicity (p=3.0 x10-13) (see Table 2). 

Predictors of time to developing LN over the disease course 
Of the 210/331 patients without LN at baseline, only 13 had a single study visit and were therefore excluded from further analyses. A total of 197/210 patients were therefore followed up longitudinally for a median of 3.1 years [interquartile range (IQR) = 1.5-5.0]. 34/197 (17%) patients developed LN during the study period after a median of 2.04 years [IQR 0.8-3.7]. In univariate Cox regression to test association with time to developing LN, the following factors had p-values of <0.2 and were included as covariates within a multiple regression model: any FH of autoimmunity, first ACR score, lymphocyte count, platelet count, C3, C4 and BILAG defined cardiorespiratory involvement (see Table 3).

After applying backward stepwise variable selection to the multiple regression model, the first ACR score (p=0.014) and C3 value (p=0.0082) were retained. Patients with a higher ACR score and a lower C3 value at baseline were at greater risk of developing LN at any point in time (ACR score: HR 1.45, 95% CI 1.08-1.95 and C3: HR 0.27, 95% CI 0.10-0.68) (see Table 4). 

In the Kaplan Meier plot for the first ACR score (Figure 1) patients are divided into two sub-groups, those with an ACR score of <=5 (n=162), and those with an ACR score >5 (n=35), on the basis that the median ACR score for those who developed LN was 5.  This plot demonstrates that at a given time, patients with an ACR score of >5 at diagnosis are at increased risk of developing LN at any one point in time (univariate analysis p=0.0038). In the Kaplan Meier plot for C3 (see Figure 2) patients are divided into two sub-groups, those with a C3 of >0.9g/L (in the normal range, n=78) or those with a C3 <=0.9g/L (hypocomplementemia, n=78). This plot demonstrates that at a given time, patients with a C3 of <=0.9g/L at diagnosis are at increased risk of developing LN (univariate analysis p=0.0032). 

[insert Figure 1.]
[insert Figure 2.]

Discussion
Using data from a national cohort of paediatric patients recruited to the UK JSLE Cohort Study, the aim of this study was to assess the ability of basic clinical and demographic factors to differentiate patients with and without LN. It also sought to determine in this real-world cohort of patients whether specific factors can be identified that can help predict which patients will subsequently develop LN. LN is one of the most serious manifestations of JSLE, with close monitoring, early detection and treatment leading to significant improvements in renal outcome  ADDIN EN.CITE []. Use of clinical data for stratification of JSLE patients as high or low risk for LN could influence the clinicians’ ‘index of suspicion’ for LN, and influence monitoring and treatment decisions. 

This study identified 37% of UK JSLE Cohort Study patients to have active LN at baseline, with a further 10% of patients developing LN after a median of 2.04 years [IQR 0.8-3.7], highlighting the early ‘high risk’ period for LN development in children. This observation is of importance to clinicians monitoring such patients, but also to researchers developing studies looking at LN. Overall, 47% of patients were identified as ever having had LN in the current study. Previous studies have reported 50-80% of JSLE patients to be affected by LN during the disease course  ADDIN EN.CITE [, , , , ]. Differences in LN prevalence between cohorts may be due to variations in patient ethnicity, the method used for active LN identification and the length of patient follow-up. Watson et al previously looked at LN prevalence within the UK JSLE Cohort Study between 2006 and 2011, demonstrating 36% of patients to have ACR defined LN and 80% to have LN if defined using a score of A, B or C in the renal domain of the BILAG score  ADDIN EN.CITE []. Within the current study, LN patients were defined on the basis of biopsy and/or a renal BILAG score of A or B only, as a score of C can be achieved through relatively minor clinical abnormalities (e.g. 1+ proteinuria on urine dipstick). 

In agreement with the current study, an inception cohort study of 256 patients with JSLE diagnosed at the Hospital for Sick Children, Toronto, has shown 37% of patients to display active LN at diagnosis (defined by the WHO biopsy classification system) with 46% having LN within the first year. After a mean follow-up of 3.5 years (3 years) 55% were described having ‘ever’ had LN  ADDIN EN.CITE []. Brunner et al reported a 78% LN prevalence in the Cincinnati JSLE cohort when LN was defined as a renal SLEDAI domain score of  >0 []. Within another US JSLE cohort from Philadelphia, 30% of patients developed LN during one month of diagnosis (defined by biopsy or meeting the ACR criteria for LN), with a further 30% developing LN within a median of 3.22 years  ADDIN EN.CITE [].  These studies also illustrate the high-risk period for LN development and the differences in LN prevalence according to the classification method. 

Six clinical and demographic factors were found in this current study to differ significantly between those with and without LN at baseline. These were: the patient’s first ACR score, presence of severe hypertension and levels of proteinuria, serum creatinine, ESR and C3 values. In contrast, Sule et al, identified low serum albumin and positive anti-dsDNA antibody levels to differentiate LN and non-LN patients in a small North American JSLE cohort  ADDIN EN.CITE []. 

Within the current study, both ACR score and C3 levels at baseline were identified as significant predictors for subsequent LN development. The study from the Toronto Hospital for Sick Children JSLE Cohort demonstrated similar results, with patients who developed renal disease more than one year after diagnosis having significantly higher SLEDAI scores at diagnosis, compared to those who did not subsequently develop LN  ADDIN EN.CITE []. Collectively, these results suggest that patients with significantly elevated SLEDAI or higher ACR scores should be closely monitored for subsequent development of LN. Within an adult SLE cohort including 109 patients, high systolic blood pressure, cutaneous vasculitis, hemoglobin < 10 mg/dl and serum creatinine > 1.3 mg/dl were identified as statistically significant risk factors for predicting LN development within a multivariate model []. Further analyses looking at larger numbers of paediatric patients and ethnically distinct patient cohorts would therefore be of interest to explore this further. 

Certain limitations of this study warrant recognition and should be addressed in future work. The patients were followed-up for a median of 2.04 years [IQR 0.8-3.7], and it would be interesting to extend this follow-up to 5, 10 and 20 years, to provide a longer-term view of the prevalence of LN in children and whether different factors were predictive of LN occurrence in the short, medium and longer term. As discussed above, LN patients were defined on the basis of biopsy and/or a renal BILAG score (A or B), however, one could explore whether the same factors appear predictive when other definitions of LN (e.g. biopsy alone, SLEDAI, ACR criteria) are utilised.

Conclusions
A considerable proportion of JSLE patients develop LN  ADDIN EN.CITE [], with early recognition and appropriate management being paramount in order to optimize renal outcomes  ADDIN EN.CITE []. Using the real-world clinical data from the UK JSLE Cohort Study, this study has explored the ability of basic clinical and demographic factors to stratify JSLE patients as high or low risk for LN at the time of their initial presentation, and during the disease course. The first two years appear to be the high-risk period for LN development in children, and clinicians should be particularly cautious when monitoring for LN during this time. Those with a large number of SLE features (reflected in their ACR score) and a low C3 count should be watched particularly carefully for future LN development. These observations are not only of importance to clinicians, but also to researchers who aim to recruit LN patients to their studies.
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Clinical and demographic factors at baseline	Active LNa(n=121)	No LN(n=210)	Odds ratio (95% CI)	pb
Proteinuriac (NAd=125)	63.1 [42, 153]	13 [8, 26]	1.08 (1.05, 1.11)	5.7x10-12
S creatininee (NA=56)	61 [45, 75]	53 [45, 62]	1.03 (1.01, 1.04)	0.00024
First ACRf Score of:	4	42/121 (35%)	112/210 (53%)	-	3.6 x10-6
	5	32/121 (26%)	60/210 (29%)	1.38 (0.78, 2.41)	
	6	22/121 (18%)	26/210 (12%)	2.25 (1.15, 4.42)	
	7	17/121 (14%)	8/210 (4%)	5.67 (2.34, 14.8)	
	8	7/121 (6%)	4/210 (2%)	4.67 (1.34, 18.6)	
	9	2/121 (1%)	0/210 (0%)	-	
Severe hypertensiong (NA=15)	14/115 (12%)	2/201 (0.5%)	13.8 (3.76, 88.9)	0.00060
ESRh (mm/h, NA=66)	60 [22, 101]	32 [13, 67]	1.01 (1.004, 1.016)	0.00075
C3i (mg/L, NA=60)	0.52 [0.35, 0.82]	0.91 [0.60, 1.21]	0.13 (0.058, 0.27)	1.3x10-7
Female gender (NA=2)	104/121 (86%)	167/208 (80%)	0.66 (0.35, 1.21)	0.20
Caucasian ethnicityj (NA=3)	53/119 (45%)	118/209 (56%)	0.62 (0.39, 0.97)	0.0349
Diagnosis age (years, NA=6)	13 [11.1, 14.5]	12.8 [10.5, 14.5]	1.02 (0.95, 1.11)	0.48
FH of autoimmunityk	58/121 (48%)	113/210 (54%)	0.79 (0.50, 1.24)	0.30
ANAl titre (NA = 129)	640 [240, 1600]	640 [400, 1140]	1.00 (0.99, 1.00)	0.83
Anti-Smm positive	26/121 (21%)	40/210 (19%)	1.16 (0.66, 2.01)	0.59
Anti- RNPn positive	27/121 (22%)	56/210 (27%)	0.79 (0.46, 1.33)	0.38
Anti-Roo positive	36/121 (30%)	57/210 (27%)	1.14 (0.69, 1.86)	0.61
Anti-Lap positive	17/121 (14%)	27/121 (22%)	1.11 (0.57, 2.11)	0.76
eGFRq (ml/min/m2, NA=92)	102 [83, 135]	113 [101, 131]	1.00 (0.99, 1.00)	0.75
Haemoglobin (g/dl, NA=23)	11.1 [9.0, 12.2]	11.3 [10.1, 12.5]	1.03 (1.00, 1.08)	0.086
WCCr (x109/L, NA=25)	5.8 [3.9, 9.6]	5.6 [4.0, 7.6]	1.08 (1.01, 1.16)	0.03
Neutrophils (x109/L, NA=37)	3.6 [2.3, 7.4]	3.4 [2.2, 5.1]	1.14 (1.05, 1.24)	0.0021
Lymphocytes (x109/L, NA = 34)	1.4 [0.8, 1.8]	1.3 [0.9, 1.9]	0.93 (0.71, 1.18)	0.56
Platelets (x109/L, NA=28)	226 [152, 315]	272 [195, 337]	0.99 (0.96, 0.99)	0.024
CRPs (mg/L, NA=62)	5 [4, 7]	5 [4, 8]	0.99 (0.98, 1.01)	0.61
C4t (g/L, NA = 63)	0.06 [0.03, 0.14]	0.11 [0.06, 0.18]	0.95 (0.92, 0.98)	0.046
dsDNAu Titre (IU/L, NA=60)	200 [34.5, 329]	53 [14.25, 200]	1.00 (0.99, 1.01)	0.16
IgGv (g/L, NA=117)	13.7 [9.8, 19.9]	16.2 [12.7, 22.7]	0.99 (0.96, 1.03)	0.45
IgAv (g/L, NA=117)	2.06 [1.33, 2.89]	1.97 [1.51, 2.57]	1.00 (0.99, 1.01)	0.55
IgMv (g/L, NA=119)	1.29 [0.77, 1.9]	1.3 [0.93, 1.9]	1.01 (0.79, 1.24)	0.88
Constitutional involvementw	66/121 (55%)	94/210 (45%)	0.81 (0.67, 0.99)	0.037
Mucocutaneous involvement	70/121 (58%)	143/210 (68%)	1.31 (1.04, 1.66)	0.062
Neuropsychiatric involvement	15/121 (12%)	21/210 (10%)	0.82 (0.61, 1.10)	0.50
Musculoskeletal involvement	66/121 (55%)	134/210 (64%)	1.25 (0.98, 1.61)	0.098
Cardiorespiratory involvement	19/121 (16%)	23/210 (11%)	0.81 (0.61, 1.06)	0.21
Gastrointestinal involvement	11/121 (9%)	13/210 (11%)	0.87 (0.60, 1.28)	0.33
Ophthalmic involvement	5/121 (4%)	3/210 (1.4%)	0.36 (0.08, 1.02)	0.14
Haematological involvement	82/121 (68%)	146/210 (70%)	0.89 (0.71, 1.11)	0.74
Table 1: Clinical and demographic data in patients with and without active Lupus Nephritis at baseline.
Summary statistics used for continuous variables (median, IQR), number count and percentage detailed for discrete variables (for each category). aLN = lupus nephritis. bp-values significance threshold Bonferroni corrected for 35 tests, therefore p<0.0014 is significant. Significant values are stated in bold font. Univariate logistic regression was used for continuous or binary distributed data and chi-square tests if variables were discrete with more than 2 categories. cBaseline Proteinuria = spot UACR or UPCR measurements depending on hospital laboratory (mg/mmolCr). dMissing data shown in brackets with NA. eS Creatinine = serum creatinine in mols/L. fACR = American College of Rheumatology. gBILAG defined severe hypertension. hESR = erythrocyte sedimentation rate. iC3 = complement factor 3. jEthnicity classification simplified to Caucasian or non-Caucasian. kAny family history of autoimmunity, see methods section. lANA = anti-nuclear antibody. mAnti-Sm = anti-Smith antibodies. nAnti-RNP = ribonuclear protein antibodies. oAnti-Ro = also known as Anti-Sjögren's-syndrome-related antigen A. pAnti-La = also known as Anti-Sjögren's-syndrome-related antigen B. qeGFR = estimated glomerular filtration rate. rWCC = white cell count. sCRP = c-reactive peptide. tC4 = complement factor 4. udsDNA = anti-double stranded DNA antibodies. vIgG/A/D = immunoglobulin types G / A / D. wBILAG defined organ domain involvement (yes = BILAG score of A/B, no = D/E). 



	Odds Ratio (95% CI)	p
Caucasian ethnicity	0.509 (0.421, 0.610)	3.0 x10-13
First ACRa Score	1.647 (1.526, 1.779)	< 2.0 x10-16
Proteinuria	1.010 (1.005, 1.007)	< 2.0 x10-16
Serum creatinine	1.013 (1.008, 1.019)	1.0 x10-16
Neutrophils (x109/L)	1.164 (1.127, 1.203)	< 2.0 x10-16
ESRb	1.007 (1.005, 1.009)	1.0 x10-16
C3c	0.373 (0.293, 0.472)	4.0 x10-16
Severe hypertension	4.657 (2.814, 7.979)	6.0 x10-9
Table 2: Output from multiple logistic regression model to predict risk of Lupus Nephritis at baseline. 
aACR = American College of Rheumatology. bESR = erythrocyte sedimentation rate. cC3 = complement factor 3.



Clinical and demographic factors 	No LN (n=163)	Act LNa (n=34)	Hazard Ratio (95% CI)	pb
Factors considered in the multivariate model	FH of autoimmunityc	85/163 (52%)	22/34 (65%)	1.22 (0.84, 1.77)	0.160
	1st ACRd Score of:	4	90/163 (55%)	15/34 (43%)	-	0.004
		5	50/163 (32%)	7/34 (21%)	1.08 (0.44, 2.66)	
		6	17/163 (10%)	7/34 (21%)	2.38 (0.97, 5.84)	
		7	4/163 (2%)	4/34 (12%)	4.20 (1.39, 12.7)	
		8	2 (1%)	1/34 (3%)	4.01 (0.52, 30.7)	
	Lymphocytese (NAf =20)	1.4 [0.9, 1.9]	1.2 [0.8, 1.7]	0.65 (0.39, 1.08)	0.098
	Platelet counte (NA=18)	283 [216, 345]	214 [149, 291]	0.997 (0.99, 1.00)	0.057
	C3g (g/L, NA=41)	0.95 [0.69, 1.25]	0.63 [0.45, 0.85]	0.23 (0.09, 0.62)	0.003
	C4h (g/L, NA=43) 	0.12 [0.08, 0.19]	0.06 [0.03, 0.12]	0.93 (0.88, 0.98)	0.004
	Cardiorespi involvement	16/163 (10%)	5/34 (14.7%)	0.82 (0.54, 1.25)	0.170
Demographics	Female gender	127/163 [78%]	29/34 [85%]	0.80 (0.31, 2.07)	0.64
	Caucasian ethnicityj	92/163 (56%)	17/34 (50%)	0.75 (0.38, 1.47)	0.40
	Diagnosis age (years, NA=1)	12.8 [10.7, 14.6]	12.6[10.4,14.1]	1.06 (0.95, 1.18)	0.31
Clinical features and laboratory investigations	ANAk titre (NA=69)	640 [400, 1140]	640 [400,1600]	1.00 (1.00, 1.00)	0.90
	Anti-Sml positive	30/163 (18%)	7/34 (21%)	1.15 (0.50, 2.64)	0.75
	Anti- RNPm positive	45/163	8/34	0.71 (0.32, 1.58)	0.40
	Anti-Ron positive	45/163	8/34	0.93 (0.42, 2.06)	0.86
	Anti-Lao positive	21/163	4/34	1.12 (0.39, 3.18)	0.84
	Sev hypertensionp (NA=8)	2/157	0/32	-	0.54
	Proteinuriaq (NA=90)	13 [8, 26]	17 [10, 28]	1.00 (0.96,1.05)	0.63
	S creatininer (NA=30)	53 [45, 62]	56 [46, 62]	1.01 (0.98, 1.04)	0.82
	eGFRs (ml/min/m, NA=48)	114 [98.7, 130.5]	108 [101, 128]	0.998 (0.99, 1.01)	0.62
	Haemoglobin (g/dl, NA=14)	11.3 [10.1, 12.4]	10.8 [9.4, 12.5]	1.02 (0.88, 1.18)	0.84
	WCCt (x109/L, NA=15)	5.8 [4.0, 7.9]	4.6 [3.9, 7.1]	0.92 (0.82, 1.05)	0.21
	Neutrophils (x109/L, NA=19)	3.4 [2.2, 5.3]	3.4 [2.2, 4.4]	0.94 (0.81, 1.10)	0.46
	ESRu (mm/h, NA=31)	32.5 [14.5, 66.3]	40 [13.5, 83.3]	0.99 (0.99, 1.01)	0.90
	CRPv (mg/L, NA=35)	5 [4, 10]	4 [3.5, 5]	1.01 (0.99, 1.03)	0.78
	dsDNAw Titre (IU/L, NA=39)	44 [11.2, 200]	96 [20, 300]	1.00 (0.99, 1.01)	0.47
	IgGx (g/L,NA=61)	15.9 [12.1, 22.7]	17 [15.2, 22.2]	1.01 (0.96, 1.07)	0.74
	IgAx (g/L, NA=60)	2.0 [1.5, 2.5]	2.1 [1.7, 3.0]	1.01 (0.99, 1.02)	0.92
	IgMx (g/L, NA=63)	1.4 [0.9, 1.8]	1.3 [1.1, 2.3]	1.1 (0.81, 1.51)	0.65
BILAG defined involvement	Constitutional involvementy	73/163 (45%)	18/34 (53%)	0.79 (0.59, 1.05)	0.44
	Mucocutaneous involvement	108/163 (66%)	27/34 (79%)	0.84 (0.6, 1.17)	0.29
	Neuropsych involvementz	17/163 (10%)	3/34 (9%)	1.12 (0.64, 1.94)	0.81
	Musculoskeletal involvement	107/163 (66%)	23/34 (68%)	1.11 (0.77, 1.59)	0.96
	Gastrointestinal involvement	9/163 (6%)	1/34 (3%)	0.87 (0.54, 2.45)	0.52
	Ophthalmic involvement	2/163 (1.2%)	1/34 (3%)	1.24 (0.11, 5.95)	0.84
	Haematological involvement	112/163 (69%)	26/34 (76%)	1.09 (0.66, 1.29)	0.48
Table 3: Clinical and demographic factors at baseline for patients with/without Lupus Nephritis longitudinally.
Summary statistics for continuous variables (median, IQR), number count and percentage detailed for discrete variables. aAct LN = Active Lupus Nephritis. bp-values are from univariate Cox Proportion hazard models. cAny family history of autoimmunity (see methods). dACR = American College of Rheumatology. eLymphocyte and platelet units = x109/L, fNA=Missing data shown in brackets. gC3 = complement factor 3. hC4 = complement factor 4. iCardioresp = BILAG defined cardiorespiratory involvement. jEthnicity simplified to Caucasian or non-Caucasian. kANA = anti-nuclear antibody. lAnti-Sm = anti-Smith antibodies. mAnti-RNP = ribonuclear protein antibodies. nAnti-Ro = also known as Anti-Sjögren's-syndrome-related antigen A. oAnti-La = also known as Anti-Sjögren's-syndrome-related antigen B. pSev Hypertension = BILAG defined severe hypertension (see methods). qBaseline Proteinuria = UPCR or UACR (mg/mmolCr). rS creatinine = serum creatinine in mols/L, seGFR = estimated glomerular filtration rate. tWCC =  white cell count. uESR = erythrocyte sedimentation rate. vCRP = c-reactive peptide. wdsDNA = anti-double stranded DNA antibodies. xIgG/A/D = immunoglobulin types G / A / D. yBILAG defined extra-renal organ domain involvement (yes = BILAG score of A/B, no = D/E). zNeuropsych = neuropsychiatric involvement.




Variables	p	HR	(95% CI)
First ACRa score 	0.014	1.45	1.08-1.95
C3b	0.0082	0.27	0.10-0.68
Table 4: Output from multiple Cox regression model where outcome was time to development of Lupus Nephritis during follow-up in those without Lupus Nephritis at baseline.
aACR = American College of Rheumatology. bC3 = complement factor 3.
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